Consequences of overutilization and underutilization of thrombolytic therapy in clinical practice. TRACE Study Group. TRAndolapril Cardiac Evaluation.

[1]  R. Califf,et al.  1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[2]  D. Tanné,et al.  Treatment and outcome of patients with acute myocardial infarction and prior cerebrovascular events in the thrombolytic era: the Israeli Thrombolytic National Survey. , 1998, Archives of internal medicine.

[3]  C. Hennekens.  The need for wider utilization of thrombolytic therapy , 1997, Clinical cardiology.

[4]  D. Ketley,et al.  Thrombolytic eligibility in acute myocardial infarction patients admitted to Norwegian hospitals. , 1997, International journal of cardiology.

[5]  E. Raftery,et al.  The association between cardiac events and myocardial ischaemia following thrombolysis in acute myocardial infarction and the impact of carvedilol. , 1996, European heart journal.

[6]  Richard P. Lewis,et al.  ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). , 1996, Journal of the American College of Cardiology.

[7]  European Cooperative Study Group,et al.  Translation of clinical trials into practice: a European population-based study of the use of thrombolysis for acute myocardial infarction , 1996, The Lancet.

[8]  D. Julian,et al.  Acute myocardial infarction: pre-hospital and in-hospital management. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. , 1996, European heart journal.

[9]  R. Califf,et al.  Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. , 1995, Circulation.

[10]  R. M. Rubison,et al.  Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. , 1994, Circulation.

[11]  C. Fry,et al.  Science of urinary incontinence Report of a Meeting of Physicians and Scientists, University College London , 1994, The Lancet.

[12]  R. Califf,et al.  Intracranial hemorrhage risk and new thrombolytic therapies in acute myocardial infarction. , 1994, The American journal of cardiology.

[13]  The TRAndolapril Cardiac Evaluation (TRACE) study: rationale, design, and baseline characteristics of the screened population. The Trace Study Group. , 1994, The American journal of cardiology.

[14]  Johan Herlitz,et al.  Indications for fibrinolytic therapy in suspected acute myocardial infarction : collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients , 1994 .

[15]  P. Kudenchuk,et al.  Hospital mortality in acute myocardial infarction in the era of reperfusion therapy (the Myocardial Infarction Triage and Intervention Project). , 1993, The American journal of cardiology.

[16]  A. Timmis,et al.  Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. , 1993, BMJ.

[17]  E. J. Brown,et al.  Selection Bias in the Use of Thrombolytic Therapy in Acute Myocardial Infarction , 1991 .

[18]  E. J. Brown,et al.  Selection bias in the use of thrombolytic therapy in acute myocardial infarction. The SAVE Investigators. , 1991, JAMA.

[19]  E. Topol,et al.  Selection of patients with acute myocardial infarction for thrombolytic therapy. , 1990, Annals of internal medicine.

[20]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  MEDICAL SCIENCE GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12 490 patients with acute myocardial infarction , 1990, The Lancet.

[21]  GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. , 1990, Lancet.

[22]  Sarah Parish,et al.  Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2.ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. , 1988, Journal of the American College of Cardiology.

[23]  E. Veys,et al.  HL-A AND INFECTIVE SACROILEITIS , 1974 .